Rachel E Thies, MD | |
900 E 54th St N Ste 200, Sioux Falls, SD 57104-0686 | |
(605) 328-9300 | |
Not Available |
Full Name | Rachel E Thies |
---|---|
Gender | Female |
Speciality | Preventive Medicine - Occupational Medicine |
Location | 900 E 54th St N Ste 200, Sioux Falls, South Dakota |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1811351802 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083X0100X | Preventive Medicine - Occupational Medicine | 12216 (South Dakota) | Primary |
Entity Name | Avera Mckennan |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1003389206 PECOS PAC ID: 0345157103 Enrollment ID: O20031110000117 |
News Archive
Results of two studies suggest that a new, investigational colorectal cancer screening test developed in a collaboration between Mayo Clinic and Exact Sciences Inc. of Madison, Wis., is highly accurate and significantly more sensitive than other noninvasive tests at detecting precancerous tumors (adenomas) and early-stage cancer.
Point of Care Anticoagulation software (PCDS AC) optimizes delivery of anticoagulation drugs and reduces adverse events associated with anticoagulation therapy. The software was designed and developed in collaboration with leading clinical thrombosis experts, and is a decision support tool that takes the complexity out of AC management by providing a real-time AC dashboard. With intuitive, predictive clinical decision support, PCDS AC transforms evidence-based guidelines into intelligent tools that measure and improve AC therapy outcomes.
Suffering from end-stage renal disease (ESRD), a growing number of patients at the Centre hospitalier de l'Université de Montréal (CHUM), have become the beneficiaries of a North American breakthrough: high efficacy hemodiafiltration (HDF).
A Yale Cancer Center clinical trial combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer disclosed a 71% pathologic complete response to the combination treatment in the initial phase I trial.
In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting -, in San Francisco, researchers will present findings that show that when women administer their own patient-controlled epidural analgesia (PCEA) instead of getting a continuous epidural infusion (CEI) they used less analgesic, but reported similar levels of satisfaction.
› Verified 2 days ago
Entity Name | Sanford Clinic |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1396764254 PECOS PAC ID: 0244143824 Enrollment ID: O20031110000532 |
News Archive
Results of two studies suggest that a new, investigational colorectal cancer screening test developed in a collaboration between Mayo Clinic and Exact Sciences Inc. of Madison, Wis., is highly accurate and significantly more sensitive than other noninvasive tests at detecting precancerous tumors (adenomas) and early-stage cancer.
Point of Care Anticoagulation software (PCDS AC) optimizes delivery of anticoagulation drugs and reduces adverse events associated with anticoagulation therapy. The software was designed and developed in collaboration with leading clinical thrombosis experts, and is a decision support tool that takes the complexity out of AC management by providing a real-time AC dashboard. With intuitive, predictive clinical decision support, PCDS AC transforms evidence-based guidelines into intelligent tools that measure and improve AC therapy outcomes.
Suffering from end-stage renal disease (ESRD), a growing number of patients at the Centre hospitalier de l'Université de Montréal (CHUM), have become the beneficiaries of a North American breakthrough: high efficacy hemodiafiltration (HDF).
A Yale Cancer Center clinical trial combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer disclosed a 71% pathologic complete response to the combination treatment in the initial phase I trial.
In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting -, in San Francisco, researchers will present findings that show that when women administer their own patient-controlled epidural analgesia (PCEA) instead of getting a continuous epidural infusion (CEI) they used less analgesic, but reported similar levels of satisfaction.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Rachel E Thies, MD 5200 S Sirocco Ave, Sioux Falls, SD 57108-6801 Ph: () - | Rachel E Thies, MD 900 E 54th St N Ste 200, Sioux Falls, SD 57104-0686 Ph: (605) 328-9300 |
News Archive
Results of two studies suggest that a new, investigational colorectal cancer screening test developed in a collaboration between Mayo Clinic and Exact Sciences Inc. of Madison, Wis., is highly accurate and significantly more sensitive than other noninvasive tests at detecting precancerous tumors (adenomas) and early-stage cancer.
Point of Care Anticoagulation software (PCDS AC) optimizes delivery of anticoagulation drugs and reduces adverse events associated with anticoagulation therapy. The software was designed and developed in collaboration with leading clinical thrombosis experts, and is a decision support tool that takes the complexity out of AC management by providing a real-time AC dashboard. With intuitive, predictive clinical decision support, PCDS AC transforms evidence-based guidelines into intelligent tools that measure and improve AC therapy outcomes.
Suffering from end-stage renal disease (ESRD), a growing number of patients at the Centre hospitalier de l'Université de Montréal (CHUM), have become the beneficiaries of a North American breakthrough: high efficacy hemodiafiltration (HDF).
A Yale Cancer Center clinical trial combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer disclosed a 71% pathologic complete response to the combination treatment in the initial phase I trial.
In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting -, in San Francisco, researchers will present findings that show that when women administer their own patient-controlled epidural analgesia (PCEA) instead of getting a continuous epidural infusion (CEI) they used less analgesic, but reported similar levels of satisfaction.
› Verified 2 days ago
Ronald Mark Rossing, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 900 E 54th St N, Sioux Falls, SD 57104 Phone: 605-328-9300 Fax: 605-328-9301 | |
Clayton Gerald Vanbalen, MD Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: 900 E 54th St N, Sioux Falls, SD 57104 Phone: 605-338-9300 Fax: 605-338-9301 | |
Bruce Alden Elkins, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 4928 N Cliff Ave, Sioux Falls, SD 57104 Phone: 605-322-5100 | |
John Alan Hansen Jr., MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1321 W 22nd St Ste Lower, Sioux Falls, SD 57105 Phone: 605-328-1990 Fax: 605-328-1991 |